ライフサイエンスコーパス: follow-up period

1 12 months (after a 6 month post-intervention follow-up period).

2 ion repeatability in the early stages of the follow up period.

3 associated with progression of HAA over the follow-up period.

4 e (MUAC) gain were found throughout the 4-wk follow-up period.

5 ose (if involved) and cost during the 5-year follow-up period.

6 as calculated and adjusted for sex, age, and follow-up period.

7 54)) in favour of exercise over the 12-month follow-up period.

8 clinical signs of bowel ischaemia during the follow-up period.

9 removed at Boston Medical Center during the follow-up period.

10 udy eyes experienced a recurrence during the follow-up period.

11 d p < 0.0001, respectively) during the short follow-up period.

12 al study eyes (18%) required them during the follow-up period.

13 ng at relapse persisted for the full 24-week follow-up period.

14 with fewer than two office visits during the follow-up period.

15 ber 31, 2011, were observed during a 32-year follow-up period.

16 and optic disc progression during an 8-year follow-up period.

17 rectomy of their remaining kidney during our follow-up period.

18 nking behaviors were assessed in the interim follow-up period.

19 ents at relapse and persisted for the entire follow-up period.

20 eye exercises performance at the end of the follow-up period.

21 y signals were observed during the long-term follow-up period.

22 hly reports of alcohol use during a 12-month follow-up period.

23 th) and cardiovascular death during a 5-year follow-up period.

24 rted secondary outcome measures, and a short follow-up period.

25 ficantly associated with DMFT throughout the follow-up period.

26 difficile-positive diarrhea during an 8-week follow-up period.

27 ars, 32683 suicides were observed during the follow-up period.

28 mia increased from 28.6% to 32.4% during the follow-up period.

29 and 95.5% completed the 3-year, double-blind follow-up period.

30 c Study of Atherosclerosis) during a 12-year follow-up period.

31 of the trial is important in determining the follow-up period.

32 horoidal detachments were encountered in the follow-up period.

33 failures throughout the 24-week posttherapy follow-up period.

34 ased risk for all-cause mortality during the follow-up period.

35 mic pantetheinase activity during the 4-week follow-up period.

36 12 patients completed the 3-month follow-up period.

37 nts were recalled every 4 to 6 months during follow-up period.

38 walking speed (yes or no) during the 4-year follow-up period.

39 P<0.001) as recurrence occurred later in the follow-up period.

40 on did not differ with study design, sex, or follow-up period.

41 lapse and persisted throughout the available follow-up period.

42 to be safe and well tolerated over the study follow-up period.

43 nd accommodation were measured over a 1-year follow-up period.

44 with peri-implant mucositis during a 6-month follow-up period.

45 6 years, 939 had at least 1 x-ray during the follow-up period.

46 at baseline and updated every 2 y during the follow-up period.

47 ents have not had an appendectomy during the follow-up period.

48 reviously treated with gallopamil during the follow-up period.

49 of whole-brain and regional atrophy over the follow-up period.

50 ability in perceived stress during a 4-month follow-up period.

51 onth treatment period, followed by a 6-month follow-up period.

52 of >/=2 dilutions (4-fold) during a 12-month follow-up period.

53 ve changes in glycemic indicators during the follow-up period.

54 or changes in glycemic indicators during the follow-up period.

55 analysis of serological status over a 2-year follow-up period.

56 e R-E group vs the NR-E group over a 1-month follow-up period.

57 d glaucoma eyes during this relatively short follow-up period.

58 kshake predicted weight variability over the follow-up period.

59 Compulsive Scale, of >/=35% over the 3-year follow-up period.

60 ording to Rome III criteria, after a 6-month follow-up period.

61 dditional 95 people died during the 38-month follow-up period.

62 nd ASCVD prognostic indicators during a long follow-up period.

63 the PCAs and serially thereafter during the follow-up period.

64 ncurring an injurious fall during the 3-year follow-up period.

65 dicted poor overall survival during a 5-year follow-up period.

66 ized at the time of diagnosis and during the follow-up period.

67 mately 64) but declined by 9 points over the follow-up period.

68 followed by a 14-day single-blinded placebo follow-up period.

69 nursing home and 9.7% died during the 1-year follow-up period.

70 vailable to take in the last 60 days of each follow-up period.

71 neurocognitive functioning during the 5-year follow-up period.

72 nce of cardiovascular disease over a 10-year follow-up period.

73 e, which then gradually increased during the follow-up period.

74 tempts (nonfatal and fatal) over the 52-week follow-up period.

75 during the 12-week intervention and 3-month follow-up periods.

76 0-0.50) and remained at 20/30 throughout all follow-up periods.

77 cruitment and extension of the treatment and follow-up periods.

78 6 [95% CI, 3.16-5.74]) averaged across the 2 follow-up periods.

79 ember 2, 2016, with 3-month intervention and follow-up periods.

80 trend of refractive error change during the follow-up periods.

81 132 participants developed HNSCC during the follow-up period (103 men and 29 women; average age at b

82 s thromboembolism was seen over the 24-month follow-up period (12% in the pharmacomechanical-thrombol

83 ulative duration of aspirin use: <20% of the follow-up period (121 nonusers) vs >/=50% of the observa

84 domization, 1 patient died during the 5-year follow-up period; 134 of the remaining 149 patients (90%

85 CI, 9.5% to 45.0%; P = .003) but not in the follow-up period (15.3% vs 8.7%; adjusted difference, 3.

86 During the follow-up period, 154 patients (5.7%) developed HGD or E

87 (10 to 27 years, T2), and at the end of the follow-up period (18 to 35 years, T3).

88 During the follow-up period, 1846 individuals had an HIV-uninfected

89 Results During the follow-up period (1979-2008), 4260 male radiologists and

90 ropathy was observed over a relatively short follow-up period (2 years) in 20 patients with evidence

91 In a median 11.5 years of follow-up period, 210 patients died (25%), including 32

92 their index endoscopy and at least a 3-year follow-up period, 25% of EACs are diagnosed within 1 yea

93 t our inclusion criteria, during the 10-year follow-up period, 28,655 (0.52%) were diagnosed with mit

94 who received health screenings over a 5-year follow-up period; 317 incidents of MS (16.1%) were obser

95 and longitudinal clinical decline (mean [SD] follow-up period, 32.1 [24.7] months [range, 6-108 month

96 383 children who returned for the full 12-mo follow-up period, 407 children (56%) and 347 children (5

97 During the follow-up period 660 (35%) participants did not have ILA

98 Over the follow-up period, 68% experienced nonpsychotic disorders

99 2 versus 1/147; P<0.001) or die during study follow-up period (7 versus 0; P=0.007).

100 n concentrations >0.01 ng/mL died within the follow-up period, 7 of which had concentrations >/=0.03

101 During the follow-up period, 9 (12%) died, either from end-stage he

102 During a 10-year follow-up period, a model combining these risk factors s

103 Three suicides occurred during the follow-up period, a rate comparable to the general popul

104 re expenditures observed during the 12-month follow-up period after incident treatment were the two o

105 he rate of recurrent disease within a 3-year follow-up period after TPTX or TPTX+AT.

106 The BRS response rate of 94% over a 1-y follow-up period allows analysis of hypothetically high

107 migrants living in Denmark during the entire follow-up period also showed a decreased risk (RR = 0.65

108 and endothelial cell density over a 3-month follow-up period analyzed by a multivariable Cox regress

109 lowing myopia progression over a twelve-year follow-up period and demonstrated a clinically acceptabl

110 low-up (PYFU) were calculated for the entire follow-up period and for 2 separate periods: the period

111 re already evident from the beginning of the follow-up period and remained largely unchanged when exc

112 Moreover, short follow-up periods and high attrition rates often impede

113 s) for sex, enrollment time, end point time, follow-up period, and advanced cirrhosis.

114 prise a small number of patients, have short follow-up periods, and lack pathologic confirmation of t

115 been limited by convenience sampling, short follow-up periods, and the inability to account for comb

116 o hospital with self-harm during the 6-month follow-up period; and cost-effectiveness of the VHS as m

117 Studies with additional patients and longer follow-up periods are needed to further explore the util

118 studies with a larger sample size and longer follow-up periods are warranted to clarify the relation

119 elative to the control group over a 12-month follow-up period as assessed by blinded diagnostic rater

120 uding 12,132 incident cases of T2D, over the follow-up period between baseline (1991-1998) and 31 Dec

121 One patient did not attend the placebo follow-up period, but was included in the final analysis

122 risk of depressive relapse within a 60-week follow-up period compared with those who did not receive

123 dren's lives, after which there was a 2-year follow-up period during which only the investigators wer

124 erity over the course of the whole trial and follow-up period (ES 0.55, 95% CI 0.14 to 0.91, p=0.004)

125 howed higher LM or aLM throughout the entire follow-up period, even after potential confounders were

126 hat adolescents who gained body fat over our follow-up period experienced an increase in striatal res

127 The mean follow-up period for incident events was 12.5 years, fro

128 postmenstrual age at initial treatment, and follow-up period for the infants receiving IVB were 24.2

129 The expense and lengthy follow-up periods for randomized clinical trials (RCTs)

130 Here we report, with a long-term follow-up period (>10 years) efficacy and safety in 68 a

131 subsequent clinical onset during the 3-year follow-up period (hazard ratio 3.29 per log pg/mL, 95% C

132 risk of depressive relapse within a 60-week follow-up period (hazard ratio, 0.79; 95% CI, 0.64-0.97)

133 F hospitalization or death during the 3-year follow-up period (hazard ratio=0.65 [95% confidence inte

134 that exhibited the greatest growth over the follow-up period in each patient.

135 Incident AF over a 20-year follow-up period in the Bruneck Study.

136 stible tobacco product averaged across the 2 follow-up periods in the unadjusted analyses (odds ratio

137 aseline, 117 developed AF during the 20-year follow-up period (incidence rate, 8.2; 95% CI, 6.8-9.6 p

138 eveloped HGD or EAC during a median 42-month follow-up period (interquartile range, 25-61 months); pa

139 Nevertheless, during the entire follow-up period, intragroup comparison demonstrated sta

140 ver, further large scale studies with longer follow up period is necessary to validate the long term

141 f eventual bleb morphology variations in the follow-up period is mandatory.

142 ch with direct lens examination and a longer follow-up period is needed to assess subtle and late adv

143 lopment of severe mental illness, and a long follow-up period is needed to identify the majority of c

144 During the follow-up period, ischemic lower-extremity PAD developed

145 During the follow-up period (Jan 1, 2011, to Dec 31, 2012), we iden

146 e incidence of CRC between groups during the follow-up period (log-rank, 0.6).

147 s of 5 to 10 years, and 277 for studies with follow-up periods longer than 10 years.

148 During the follow-up period, MACE occurred in 346 (32.5%) in the gr

149 Results During the follow-up period (mean follow-up, 7(1/2) years), 7137 in

150 Over the follow-up period, mean time in the glucose concentration

151 d 7598 nerve events were recorded during the follow-up period (median 5.0 years, IQR 4.5-5.0).

152 ome was development of HGD or EAC during the follow-up period (median, 5.9 years).

153 east 1 additional intraocular surgery in the follow-up period, most commonly for cataract extraction

154 During the follow up period, no significant IOP difference was foun

155 SDOCT follow-up period of >1 year (3.1 +/- 1.4 years).

156 an follow-up was 4.1 years with 43% having a follow-up period of >5 years.

157 ab (average number of injections 5.7) in the follow-up period of 1 to 12 months, was associated with

158 atients was -0.12+/-0.51 dB/year over a mean follow-up period of 10.4+/-3.7 years.

159 fulfilled the inclusion criteria with a mean follow-up period of 109.22 +/- 35.7 months or approximat

160 antipsoriatic medication provided, during a follow-up period of 11 years and 7 months.

161 During the follow-up period of 11 years, the patient also developed

162 in resistance at baseline and after a median follow-up period of 11.3 (range 7.3-13.4) years in 97 Fi

163 nd 59 safety communications) during a median follow-up period of 11.7 years (interquartile range [IQR

164 ll, 226 women developed MS during an average follow-up period of 11.7 years.

165 vs cases was 75% vs 0% (P = .007) at a mean follow-up period of 12 months in both groups.

166 All patients had a minimum follow-up period of 12 months.

167 vascular disease incidence during an average follow-up period of 12 years.

168 by food-frequency questionnaire.Over a mean follow-up period of 12.4 y, 3259 (31%) deaths occurred.

169 Over a median follow-up period of 12.6 years (range, 0.3-35.1 y), 193

170 : 3.75; 95% CI: 1.26 to 11.2) over a maximum follow-up period of 14 years (median 3.8 years [interqua

171 After a median follow-up period of 14.7 months, hepatotoxicity was foun

172 cardiovascular disease risk factors.During a follow-up period of 15,947 person-years, 238 of 1226 (19

173 Over a mean postdonation follow-up period of 16.3 years, 26.7% of pancreas donors

174 151,441 (32.7%) patients died during a mean follow-up period of 18.0 months.

175 Over a median follow-up period of 19 years, 158 of the 1690 HBV carrie

176 reatic cysts remained stable during a median follow-up period of 2.2 years; however, in 27% of patien

177 sis, 61% (504 of 830) died during the median follow-up period of 2.26 years.

178 2,397 (14.2%) receiving ADT during a median follow-up period of 2.7 years (interquartile range, 1.0-

179 or infection leading to removal after a mean follow-up period of 22 months (range, 12-31mos.).

180 ans, and 671 deaths occurred during a median follow-up period of 22.5 years (1987-2011).

181 Over a median follow-up period of 25 months, 1.3% (57 of 4347) sustain

182 After a median follow-up period of 26 months (interquartile range, 20-3

183 pitalization (with alpha=0.03) over a median follow-up period of 3 years.

184 After a mean follow-up period of 3.1 years (range, 1-6 years), the mi

185 s in the United States and Canada for a mean follow-up period of 30.5 months from August 1, 2005, to

186 control of intraocular pressure over a mean follow-up period of 33.68 months (1-90 months).

187 nt duration of 20.3+/-16.0 months and a mean follow-up period of 34.1+/-13.4 months.

188 During a median follow-up period of 36.7 months, 1929 deaths occurred (8

189 Over a mean follow-up period of 37.5+/-20.2 months (range, 3-60 mont

190 mplants were clinically stable during a mean follow-up period of 39.2 months.

191 During a median follow-up period of 4.0 years, it was observed that play

192 During the median follow-up period of 4.1 years, the primary outcome occur

193 During a median follow-up period of 4.2 years (range, 0-9 years), elderl

194 ) experienced decompensation during a median follow-up period of 4.22 years.

195 Z line developed HGD or EAC during a median follow-up period of 4.8 years (interquartile range, 3.2-

196 atients, and VAs recurred in 4 during a mean follow-up period of 41+/-24 months.

197 After a mean follow-up period of 41.4 +/- 29.0 months, patients with

198 During the follow-up period of 42 (range, 17-142) months 576 patien

199 (SD +/- 9.8) anti-VEGF injections and a mean follow-up period of 45.3 months (SD +/- 10.5) were inclu

200 Seven patients with a mean follow-up period of 47 +/- 38 months after the occurrenc

201 Over a follow-up period of 48 weeks, 37 patients remained absti

202 With a maximum follow-up period of 5 years, adverse clinical outcomes o

203 During a mean follow-up period of 5.1 (standard deviation, 2.7) years,

204 ient survival rate was 96.4% during the mean follow-up period of 57.0 +/- 22.4 months.

205 y among 4036 patients with CD, with a median follow-up period of 58 months.

206 After a median follow-up period of 58.2 months, 668 patients (50.5%) ac

207 resumption of regular menses after a minimal follow-up period of 6 months following chemotherapy was

208 ve response following a prespecified minimum follow-up period of 6 months, assessed by an independent

209 o longer required opioid therapy at a median follow-up period of 6 months.

210 During a median follow-up period of 6.3 years, the cumulative incidence

211 At a median follow-up period of 6.4 years, the median EFS was 3.4 ye

212 men) and LQT2 (n=161; 41% men) over the mean follow-up period of 6.4+/-3.9 years.

213 Over a median follow-up period of 6.5 years, we identified 2593 first

214 During a mean follow-up period of 6.7 (5.9) years, 588 patients (30.6%

215 After a median follow-up period of 67.6 months, the primary outcome had

216 After an average follow-up period of 7 years (2000-2010), the authors fou

217 oints between 2000 and 2010, with an average follow-up period of 7 years.

218 After a median follow-up period of 7.4 months, the median progression-f

219 During a mean (+/- SD) follow-up period of 7.9 +/- 3.6 y, 779 participants deve

220 After a median follow-up period of 75 months, 63 patients (74%) had an

221 After a median follow-up period of 8 y from age 26 y, we found that TBI

222 Results With a mean follow-up period of 8 years, the mean percent change in

223 During a mean follow-up period of 8.1 years, 55 185 individuals (3.0%)

224 During a median follow-up period of 8.4 years, 1,603 women and 951 men s

225 t wellbeing quartile died during the average follow-up period of 8.5 years compared with 9.3% of thos

226 During a mean follow-up period of 83.8 +/- 57.3 months, spontaneous su

227 During a median follow-up period of 9.3 years, 227 women (9.9% of female

228 ad to report on all-cause mortality during a follow-up period of at least 12 months and be published

229 each group, with minimum 10 participants and follow-up period of at least 6 months, were included.

230 n November 2001 and July 2007, with a median follow-up period of more than 9 years.

231 median age, visual field mean deviation, and follow-up period of the ODH+ and ODH- groups was 77.5 an

232 The mean follow-up period of the patients was 46 months (range: 3

233 RCTs) and prospective controlled trials with follow-up periods of >/= 6 months that compared the perf

234 In a meta-analysis of 10 studies with follow-up periods of >/=5 years (a total of 239 EACs), 2

235 of 3 months to 1 year, 494 for studies with follow-up periods of 1 to 5 years, 366 for studies with

236 000 patients-years were 654 for studies with follow-up periods of 3 months to 1 year, 494 for studies

237 eriods of 1 to 5 years, 366 for studies with follow-up periods of 5 to 10 years, and 277 for studies

238 iably characterized in recipient plasma over follow-up periods of up to 5 years.

239 There were 37 deaths during the follow-up period, of which none were due to hepatitis B

240 thromboembolism rates (number of events per follow-up period) or RR estimates.

241 n of a combination of these drugs during the follow-up period, or were temporary residents.

242 ive of changes in global T scores during the follow-up period (P = .14).

243 that remained asymptomatic (23%) within the follow-up period (P = 0.005).

244 ge of 2.0 units in the GDS scores during the follow-up period (P = 0.025).

245 only showed stable frailty over the 30-month follow-up period (P value for differences over time by a

246 ve values (P < .001) and compared in between follow-up periods (P </= .010).

247 h low-grade dysplasia) and at least a 3-year follow-up period, providing data on missed and incident

248 PVA in the eye with better vision during the follow-up period (PVA gain of >/=2 lines [+0.2 logMAR],

249 ic-compliance (EC) group with at least a 5-y follow-up period, qualified for the meta-analysis.

250 of 46 health care visits per year during the follow-up period (range, 3-196 visits per year; standard

251 nts in whom visual acuity decreased over the follow-up period recorded a reduction in central retinal

252 decrease in pressures (mm Hg-day) during the follow-up period relative to the baseline pressure.

253 d without chronic persistent DME through the follow-up period, respectively, by a mean of 7 letters a

254 umans who gained body fat over a 2 or 3 year follow-up period show an increase in responsivity of rew

255 11 participants died during the study follow-up period (six in the 9vHPV vaccine group and fiv

256 In Kaplan-Meier analysis over a 5-year follow-up period, survival was significantly worse if th

257 T0), 6 months after surgery (T1), during the follow up period (T2) (mean 15.3 years), and at the end

258 T2) (mean 15.3 years), and at the end of the follow-up period (T3) over 25 years.

259 ven RCTs that included 543 participants with follow-up periods that ranged from 1 to 6 mo (mean: 3.6

260 During a 3-month follow-up period, the intervention was discontinued.

261 During the follow-up period, the magnitude of change in 6MWD differ

262 At the end of the follow-up period, the mean post-operative best-corrected

263 During follow-up period, the mortality rate of 91 patients who

264 o hospital with self-harm during the 6-month follow-up period; the number of times a participant re-p

265 Over the 6-month follow-up period, there was a statistically significant,

266 In the 42-year follow-up period, there were 781 deaths.

267 mpared with those who did not die during the follow-up period (TNF-alpha: median, 1.92 pg/mL; interqu

268 tical method accounting for censoring in the follow-up period to a nationwide twin sample.

269 migration data were obtained throughout the follow-up period up to December 2008.

270 ractive error of myopic children in a longer follow-up period (up to 12 years).

271 The follow-up period varied based on the date when recruitme

272 The median imaging follow-up period was 2.2 years (IQR, 1.2-3.9 years; rang

273 The mean follow-up period was 21.3 months (range, 3-59 months).

274 The mean follow-up period was 24.9+/-19.4 months.

275 rquartile range 2.7-5 years), and the median follow-up period was 3.75 years.

276 The mean follow-up period was 31 (range 3.6-61.3) months.

277 The median follow-up period was 43 months.

278 The mean follow-up period was 5.9 years.

279 The median follow-up period was 69 months (range, 6-126 months).

280 ntenance of a PPG value <12 mm Hg during the follow-up period was associated with a lower risk of rec

281 e current analysis of data from the extended follow-up period was considered to be exploratory.

282 Average or cumulative exposure over the follow-up period was less strongly associated with sensi

283 al and morphologic parameters throughout the follow-up period was observed in the eyes that did not u

284 sions was achieved and recanalization in the follow-up period was revealed.

285 Mortality within the follow-up period was the primary end point.

286 Throughout the 5-year follow-up period, we collected self-reported acute respi

287 death with a functioning graft over a 6-year follow-up period were examined in unadjusted and adjuste

288 lizations for AMI and stroke within a 5-year follow-up period were identified in exudative AMD benefi

289 who developed Parkinson's disease during the follow-up period were identified.

290 occurring during treatment and the 12-month follow-up period were recorded and evaluated.

291 Results for the 10-year follow-up period were similar.

292 The median follow-up periods were 28.4 and 27.4 mo for i-PET and Eo

293 gans except intestine were included, and the follow-up periods were 5 and 10 years.

294 sitivity analyses and whether 1- or 2.5-year follow-up periods were analyzed.

295 CCT measurements by dual Scheimpflug, at all follow-up periods, were lower compared to mean baseline

296 he continental United States for a 2000-2009 follow-up period when matching census tract-level PM2.5

297 .1% experienced GR depth increase during the follow-up period, whereas the remaining experienced decr

298 oidal flow void on OCTA persisted during the follow-up period, while the abnormal hyperreflectance of

299 study and were assessed annually over a 3-y follow-up period with 127 participants completing the fi

300 ence and recurrence of asthma over a 10-year follow-up period within a population-based birth cohort